AADR vs CNCR

Both AADR and CNCR are ETFs. AADR has a higher 5-year return than CNCR (9.29% vs 2.21%). AADR has a higher expense ratio than CNCR (1.1% vs 0.79%). Below is the comparison between AADR and CNCR.

AADR CNCR
Segment Equity: Global Ex-U.S. - Total Market Growth Equity: U.S. Biotech
Issuer AdvisorShares Exchange Traded Concepts
Net Assets $69.25M $38.19M
Expense Ratio 1.10% 0.79%
Management Style passive (index-based) passive (index-based)
Dividend Yield 0.68% 0.00%
Underlying Index -- Loncar Cancer Immunotherapy Index
YTD Return 6.83% 26.08%
1-Year Return 19.02% 60.09%
3-Year Return 0.44% 3.77%
5-Year Return 9.29% 2.21%
10-Year Return 7.79% N/A

AADR description

The Fund seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index and the BNY Mellon Classic ADR Index. The Fund selects a portfolio of U.S. traded securities of non-U.S. organizations, most often American Depositary Receipts (ADRs), included in the BNY Mellon Classic ADR Index.

AADR performance & returns

YTD Return 6.83%
1-Month Return 1.54%
3-Month Return 2.74%
1-Year Return 19.02%
3-Year Return 0.44%
5-Year Return 9.29%
10-Year Return 7.79%
AADR expense ratio is 1.1%.

AADR holdings

Top 10 Holdings (46.22% of Total Assets)

Name Symbol % Assets
MercadoLibre Inc MELI.SA 5.89%
argenx SE ADR ARGX 5.63%
NICE Ltd ADR NICE 5.45%
Gold Fields Ltd ADR GFI.JO 5.07%
Galapagos NV ADR GLPG 4.76%
Anglogold Ashanti Ltd ADR AU.JO 4.67%
ZTO Express (Cayman) Inc ADR ZTO 4.27%
TAL Education Group ADR TAL 3.75%
ASML Holding NV ADR ASML 3.67%
AstraZeneca PLC ADR AZN.L 3.06%

Other relevant AADR comparisons

You may also want to check out the following AADR comparisons that investors often look for on Finny

Or use Finny Compare Wizard to create a comparison you’d like to see.

CNCR description

The Fund seeks to track the total return performance of the Loncar Cancer Immunotherapy Index. The Index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer.

CNCR performance & returns

YTD Return 26.08%
1-Month Return 5.06%
3-Month Return 9.18%
1-Year Return 60.09%
3-Year Return 3.77%
5-Year Return 2.21%
10-Year Return N/A
CNCR expense ratio is 0.79%.

CNCR holdings

Top 10 Holdings (37.34% of Total Assets)

Name Symbol % Assets
Macrogenics Inc MGNX 4.31%
BioNTech SE ADR BNTX.DE 4.19%
CRISPR Therapeutics AG CRSP 3.76%
IGM Biosciences Inc Ordinary Shares IGMS 3.69%
Replimune Group Inc REPL 3.69%
Legend Biotech Corp ADR LEGN 3.59%
Compugen Ltd CGEN 3.58%
Fate Therapeutics Inc FATE 3.52%
BeiGene Ltd ADR BGNE 3.52%
Nektar Therapeutics NKTR 3.49%

Other relevant CNCR comparisons

You may also want to check out the following CNCR comparisons that investors often look for on Finny

    Or use Finny Compare Wizard to create a comparison you’d like to see.

    You can check out all comparisons Finny users have looked for here. Feel free to the browse the list and view the comparisons that are of an interest to you.

    7-day free trial: Get unlimited comparisons, and stock, ETF and mutual fund analyses for just $14.95 a month, without ads. Start a free trial. Go ad free!

    Follow Us